Kiadis Pharma Raises Euro 15 million to Advance Oncology Pipeline

    San Francisco-Based Alta Partners Joins as Lead Investor

    AMSTERDAM, June 26 /CNW/ - Oncology product development company Kiadis
Pharma announced today that it has completed a Euro 15 million private
financing round. Alta Partners, a prominent life science venture capital
company based in San Francisco, led the financing round. Other major new
investors include Quest for Growth and MedSciences Capital. All of the major
existing investors also contributed to this round, including founding investor
Life Sciences Partners, Esprit Capital Partners LLP and N.V. NOM (Investment
and Development Agency for the Northern Netherlands).
    The Kiadis Pharma product pipeline is focused on providing novel
treatments for significant unmet medical needs in the field of bone marrow
transplants and the treatment of aggressive cancers. The four most advanced
products are currently in clinical trials, ranging from Phase I to entering
Phase III. Kiadis Pharma's lead product is ATIR, which enables the use of
mismatched bone-marrow donors in transplantations for terminally ill blood
cancer patients. Kiadis Pharma is a Dutch company with locations in The
Netherlands and Canada.
    Ekaterina Smirnyagina, of Alta Partners, joining the Supervisory Board of
Kiadis, added: "We were impressed by the broad endorsement of Kiadis' clinical
programs within the international scientific community. Its lead product,
ATIR, is being tested by opinion leaders in the field as a potentially
life-saving treatment option for patients unable to find a matched bone-marrow
donor, while also preventing graft-versus-host disease (GvHD). We look forward
to working with the seasoned management of Kiadis and its investors on
building a premier oncology company".
    Mark Wegter, Chairman of the Supervisory Board of Kiadis Pharma and
General Partner at LSP, commented: "Following the acquisition of Celmed late
last year, this is yet again a key milestone that has been achieved by the
company and its management. It marks the next step in the further growth of
Kiadis Pharma which we feel is positioned to become a major force in the
European biotech arena. We are very pleased to see our excitement about the
company being shared by other high quality US and European investors."
    Manja Bouman, CEO, Kiadis Pharma, stated: "We are delighted by this
latest funding round. Our shareholders provide a particularly strong knowledge
base with an excellent track record in life sciences. Bringing in Alta
Partners as our lead investor is an important external validation. Not only
does it confirm the potential of many of our clinical trials, but it also
demonstrates the overall confidence of sophisticated investors in our novel
    She added: "Earlier this year we announced the trial of our ATIR product
on nine end-stage blood cancer patients who were transplanted in the
mismatched setting with the use of ATIR. All patients responded well. This
treatment is at a very exciting stage in its development and this trial was an
important milestone in our revolutionary approach to providing successful
mismatch transplants for end stage blood cancer patients."

    About Kiadis Pharma
    Kiadis Pharma is an oncology focused pharmaceutical company with four
programs in different phases of clinical development. The company develops
products that offer new treatment options for terminally ill cancer patients
and address significant unmet medical needs. Key areas for Kiadis Pharma are
clinical indications in blood cancers and solid tumors. Kiadis Pharma is
headquartered in the Netherlands with facilities in Groningen, the Netherlands
and Montreal, Canada. For more information about Kiadis Pharma, please visit

    About Alta Partners
    Alta Partners is a San Francisco-based venture capital firm focused on
life sciences investing. Founded in 1996, the firm currently manages
$2 billion in committed capital through eight venture fund programs. Alta
invests in life sciences companies across the development continuum, from
company formation to later-stage opportunities, and has funded more than 110
companies in the sector to date.

    About LSP
    LSP (Life Sciences Partners) is a leading independent
European-headquartered venture capital firm, providing private equity
financing to early- to mid-stage life-science companies. With EUR 400 million
under management and offices in Amsterdam, Munich and Boston. For more
information about the LSP Group, please visit the website at

    About MedSciences Capital
    MedSciences Capital ( is an Amsterdam-based
investor in early- to mid-stage medical life sciences companies. MedSciences
Capital operates as a part of the Dutch merchant bank, Kempen & Co N.V.

For further information:

For further information: Kiadis Pharma B.V., Dr. Manja Bouman, CEO,
Email:, Telephone: +31 (0)50 547 4270; Alta Partners,
Jennifer James, Director of Marketing and Communications, Email:, Telephone: (415) 362-4022; LSP, Mark Wegter, General
partner, Email:, Telephone: +31 (0)20 664 5500; MedSciences
Capital, Willem van Lawick, MD, MBA, Director, Email:, Telephone: +31 (0)20 348 8702

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890